Liver Disease, Multimorbidity
and Lifestyle

Journal: Lancet Gastroenterol Hepatol. 2025 Oct;10(10):924-940. doi.org/10.1016/s2468-1253(25)00128-1

Authors: Wong VW, Amin NB, Takahashi H, Darekar A, Tacke F, Kiszko J, Rodriguez H, Nakajima A, Alkhouri N, Charlton M, Anstee QM

Cookies user preferences

We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.

Accept all

Decline all

Analytics

Tools used to analyse the data to measure the effectiveness of a website and to understand how it works.

Google Analytics

Decline

Save preferences

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study